title: Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
abstract: miRNAs are non-coding RNA molecules; their deregulations may contribute to cancer pathogenesis. However, the mechanisms of how miRNA dysfunction contributes to the lymphomagenesis of diffuse large B-cell lymphoma (DLBCL) are not well established. In this study, we analyzed the expression of miR-224 in four DLBCL cell lines and 168 patients' specimens. We found that the expression of miR-224 in DLBCL was down-regulated compared with normal B-cell but was not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type. Using bioinformatics prediction and luciferase report assays, we demonstrated that miR-224 directly down-regulated CD59 expression by binding to its 3'-untranslated region. We also used immunohistochemical staining of CD59 in human DLBCL specimens and analyzed the relationship between the expression of miR-224, CD59 and the overall/progress-free survival of DLBCL patients who were uniformly treated with rituximab,cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). We found that miR-224 may contribute to DLBCL pathogenesis. Most importantly, the expression of miR-224 and CD59 can predict the response and outcome of DLBCL patients treated with R-CHOP.
authors.forename: Guoqi
authors.initials: G
authors.lastname: Song
authors.forename: Guorong
authors.initials: G
authors.lastname: Song
authors.forename: Huiyun
authors.initials: H
authors.lastname: Ni
authors.forename: Ling
authors.initials: L
authors.lastname: Gu
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Baoan
authors.initials: B
authors.lastname: Chen
authors.forename: Bangshun
authors.initials: B
authors.lastname: He
authors.forename: Yuqin
authors.initials: Y
authors.lastname: Pan
authors.forename: Shukui
authors.initials: S
authors.lastname: Wang
authors.affiliation: Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China. shukuiwang1967@163.com.
authors.forename: William C
authors.initials: WC
authors.lastname: Cho
mesh_terms: D020413:3' Untranslated Regions; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D018957:CD59 Antigens / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000627:therapeutic use; D015536:Down-Regulation; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D017930:Genes, Reporter; D006801:Humans; D007150:Immunohistochemistry; D008221:Lymphoid Tissue / Q000378:metabolism / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000378:metabolism; D000069283:Rituximab; D016019:Survival Analysis; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D020413:3' Untranslated Regions; D058846:Antibodies, Monoclonal, Murine-Derived; D018957:CD59 Antigens; C546140:MIRN224 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; C571759:R-CHOP protocol; D011994:Recombinant Proteins; C051590:CD59 protein, human; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone